
Oliver Brandicourt joins Bayer from Pfizer
pharmafile | September 30, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, Oliver Brandicourt, Pfizer
Bayer Healthcare has appointed Pfizer’s executive Olivier Brandicourt to head up its healthcare division.
Taking over from interim head Wolfgang Plischke from 1 Nov, Germany’s biggest drug firm said Brandicourt, who was a member of Pfizer’s executive leadership team, will be responsible for taking new drugs to market.
The previous head of Bayer, Joerg Reinhardt, resigned in February to become chairman of Novartis .
“With Olivier Brandicourt we have found a strong leader with outstanding international experience and a successful track record in the healthcare industry,” said Bayer chief executive Marijn Dekkers.
Speaking about his new role, Brandicourt said he was: “Looking forward to joining the Bayer team”, adding that the group has a clear focus on research and development as well as a passion and dedication to improving people’s lives.
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …






